Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Placebo-controlled, Double-blind Phase 2 Study of Patritumab (U3-1287) in Combination With Cetuximab Plus Platinum-based Therapy in First Line Setting in Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Next Previous
Trial Profile

Randomized, Placebo-controlled, Double-blind Phase 2 Study of Patritumab (U3-1287) in Combination With Cetuximab Plus Platinum-based Therapy in First Line Setting in Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Patritumab (Primary) ; Carboplatin; Cetuximab; Cisplatin
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Sponsors Daiichi Sankyo Company

Most Recent Events

  • 12 Oct 2019 Primary endpoint has not been met. (Progression Free Survival (PFS) in the Heregulin (HRG)-High Expression Population)
  • 12 Oct 2019 Results evaluating safety, efficacy and pharmacokinetics of first-line cetuximab plus cisplatin or carboplatin with either patritumab or placebo in patients with squamous cell carcinoma of the head and neck published in the European Journal of Cancer
  • 12 Dec 2018 Status changed to discontinued.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top